204 related articles for article (PubMed ID: 12635450)
1. Galantamine hydrobromide: an agent for Alzheimer's disease.
Zarotsky V; Sramek JJ; Cutler NR
Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
[TBL] [Abstract][Full Text] [Related]
2. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
3. Galantamine: a review of its use in Alzheimer's disease.
Scott LJ; Goa KL
Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
[TBL] [Abstract][Full Text] [Related]
4. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
5. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J; García G
Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
[TBL] [Abstract][Full Text] [Related]
6. Current status and new developments with galantamine in the treatment of Alzheimer's disease.
Tariot P
Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333
[TBL] [Abstract][Full Text] [Related]
7. Update on Alzheimer drugs (galantamine).
Raskind MA
Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
[TBL] [Abstract][Full Text] [Related]
8. Galantamine in Alzheimer's disease.
Razay G; Wilcock GK
Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
10. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
[TBL] [Abstract][Full Text] [Related]
11. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
13. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
Coyle JT; Geerts H; Sorra K; Amatniek J
J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
[TBL] [Abstract][Full Text] [Related]
14. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
15. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
[TBL] [Abstract][Full Text] [Related]
16. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
Samochocki M; Zerlin M; Jostock R; Groot Kormelink PJ; Luyten WH; Albuquerque EX; Maelicke A
Acta Neurol Scand Suppl; 2000; 176():68-73. PubMed ID: 11261808
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.
Migliaccio-Walle K; Getsios D; Caro JJ; Ishak KJ; O'Brien JA; Papadopoulos G;
Clin Ther; 2003 Jun; 25(6):1806-25. PubMed ID: 12860500
[TBL] [Abstract][Full Text] [Related]
18. [Nicotinic Receptor, galantamine and Alzheimer disease].
Arroyo G; Aldea M; Fuentealba J; García AG
Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
[TBL] [Abstract][Full Text] [Related]
19. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
20. Galantamine: use in Alzheimer's disease and related disorders.
Bullock R
Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
